Human BioSystems
Human BioSystems: Human BioSystems Completes Platelet Testing at Second Independent Laboratory
Corporate news transmitted by DGAP – a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
——————————————————————————
Breaking News: Human BioSystems Completes Platelet Testing at Second
Independent Laboratory
Palo Alto, CA – July 5, 2005 – (OTCBB:HBSC) -Human BioSystems (“HBS”), a
developer of preservation platforms for organs and other biomaterials,
specializing in the development of proprietary above zero (“HBS-AZ”) and
below zero (“HBS-BZ”) organ and tissue preservation systems and methods for
preserving blood platelets, announced today that it has completed blood
platelet testing at a second independent laboratory.
“Under an agreement signed in June 2005, the laboratory has assisted HBS in
testing our methods and protocols for extending the shelf life of blood
platelets,” said Dr. David Winter, President of Human BioSystems.
This second in-vitro study involving the cold storage of human platelets
started in January of 2006 was recently completed. Ten subjects were
involved and the results were consistent with those of a previous
independent study. Both of these studies utilized technology covered by a
patent application for which HBS has received a Notice of Allowability.
HBS is now preparing to submit an application to the FDA within the next
few months in order to obtain a license for conducting human infusion
studies. Favorable test results should position HBS for strategic
partnering and licensing of its technology.
Blood platelets are the clotting component of blood and are collected from
donors and infused into cancer patients who have undergone chemotherapy
and/or radiation treatments. Such treatments inhibit the production of
platelets for a period of time, possibly resulting in bleeding without
regular platelet infusion.
“Currently, platelets have an FDA mandated five day shelf life. It is our
goal to extend the shelf life by utilizing the proprietary HBS solution and
process to preserve platelets at refrigerated temperatures for at least
seven or more days,” according to Dr. Winter.
“We believe that when our technology is brought to market it should
drastically reduce the outdating of platelets, allowing blood centers to
significantly reduce their costs without changing their existing basic
procedures. The total worldwide loss due to outdating is estimated by HBS
to exceed one billion dollars at the hospital level based on 6 million
transfusion units collected annually and an outdate percentage of 15%.
Refrigeration should inhibit bacteria growth, resulting in a safer
product,” added Harry Masuda, CEO of Human BioSystems.
HBS is headquartered in Palo Alto, California with research facilities in
Michigan.
For further information about this release and the Company, contact Harry
Masuda, CEO, Human BioSystems, phone # 650-323-0943,
hmasuda@humanbiosystems.com and/or contact Rich Kaiser, Investor Relations,
YES INTERNATIONAL, phone # 800-631-8127, yes@yesinternational.com.
Certain statements contained herein are “forward-looking” statements (as
such term is defined in the Private Securities Litigation Reform Act of
1995). Because such statements include risks and uncertainties, actual
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause results to differ
materially from those expressed or implied by such forward-looking
statements include, but are not limited to, results from ongoing research
and development as well as clinical studies, failure to obtain regulatory
approval for human studies, failure to obtain regulatory approval for the
Company’s products, if required, failure to develop a product based on the
Company’s technology, issues with the patentability and/or protection of
the Company’s technology, failure of any such products to compete
effectively with existing products, the inability to find a strategic
partner or to consummate a relationship with a potential strategic partner
on acceptable terms, and other factors discussed in filings made by the
Company with the Securities and Exchange Commission
(c)DGAP 11.07.2006
—————————————————————————
Latest News
Latest Reports
Upcoming Events
No Events found